{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:45:34Z","timestamp":1792633534196,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Local failure and leptomeningeal disease (LMD) are both poor outcomes that can occur after resection and post-operative radiosurgery for newly diagnosed brain metastases (BM). There is increasing utilization of collagen-embedded Cesium-131 brachytherapy (GammaTile\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) as a method of providing immediate adjuvant radiation therapy. Post-operative LMD rates following GammaTile implantation for newly diagnosed BMs has yet to be reported. The objective was to evaluate the incidence of LMD rates, local control (LC), and survival following resection and GammaTile for newly diagnosed BMs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An ongoing, multicenter, prospective, observational Phase IV non-interventional registry (NCT0442738) was queried to analyze rates of LMD following surgical resection of newly diagnosed BMs. Following resection and GammaTile implantation, we evaluated LMD rates, LC, and overall survival (OS). The Kaplan-Meier method was used to analyze time-to-event outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-one patients with 55 BMs were analyzed. The median follow-up was 12.4\u2009months. The majority of BMs were in the supratentorial brain (87.3%). Four patients (7.8%) experienced LMD, 3 pachymeningeal and 1 classical. The 3-, 6-, and 12-month LMD-free rates were 97.4%, 94.1%, and 88.5%, respectively. The 12-month LC was 92.3%, and the 12-month OS was 49.0% with a median OS of 11.0\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this prospective registry study, GammaTile at the time of resection of newly diagnosed BMs was associated with high rates of tumor control and modest rates of LMD. As the trial registry continues to accrue, further data will continue to shed light on variables associated with outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05455-0","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:19:54Z","timestamp":1770455994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Local control and leptomeningeal disease after resection and GammaTile brachytherapy for newly diagnosed brain metastases: results from a prospective registry"],"prefix":"10.1007","volume":"176","author":[{"given":"Trent","family":"Kite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hanft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sean","family":"Peach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"DiNapoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Sevak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette J.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wasilewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney E.","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene C.","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"2","key":"5455_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3171\/2022.12.JNS221490","volume":"139","author":"RA Morshed","year":"2023","unstructured":"Morshed RA, Saggi S, Cummins DD et al (2023) Identification of risk factors associated with leptomeningeal disease after resection of brain metastases. J. Neurosurg 139(2):402\u2013413","journal-title":"J. Neurosurg"},{"issue":"8","key":"5455_CR2","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","volume":"18","author":"A Mahajan","year":"2017","unstructured":"Mahajan A, Ahmed S, McAleer MF et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040\u20131048","journal-title":"Lancet Oncol"},{"issue":"2","key":"5455_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3171\/JNS\/2008\/108\/2\/0248","volume":"108","author":"D Suki","year":"2008","unstructured":"Suki D, Abouassi H, Patel AJ et al (2008) Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 108(2):248\u2013257","journal-title":"J Neurosurg"},{"issue":"4","key":"5455_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1227\/01.NEU.0000341535.53720.3E","volume":"64","author":"D Suki","year":"2009","unstructured":"Suki D, Hatiboglu MA, Patel AJ et al (2009) Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. Neurosurgery 64(4):664\u2013674; discussion 674-676","journal-title":"Neurosurgery"},{"key":"5455_CR5","doi-asserted-by":"crossref","unstructured":"Tewarie IA, Jessurun CAC, Hulsbergen AFC, Smith TR, Mekary RA, Broekman MLD (2021) Leptomeningeal disease in neurosurgical brain metastases patients: a systematic review and meta-analysis. Neurooncol Adv 3(1):vdab162","DOI":"10.1093\/noajnl\/vdab162"},{"issue":"4","key":"5455_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ijrobp.2019.11.022","volume":"106","author":"S Shi","year":"2020","unstructured":"Shi S, Sandhu N, Jin MC et al (2020) Stereotactic radiosurgery for resected brain metastases: single-institutional experience of over 500 cavities. Int J Radiat Oncol Biol Phys 106(4):764\u2013771","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"5455_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","volume":"5","author":"B Gleissner","year":"2006","unstructured":"Gleissner B, Chamberlain MC (2006) Neoplastic meningitis. Lancet Neurol 5(5):443\u2013452","journal-title":"Lancet Neurol"},{"issue":"1","key":"5455_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cncr.30911","volume":"124","author":"N Wang","year":"2018","unstructured":"Wang N, Bertalan MS, Brastianos PK (2018) Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer 124(1):21\u201335","journal-title":"Cancer"},{"issue":"2","key":"5455_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11060-017-2666-7","volume":"136","author":"R Ma","year":"2018","unstructured":"Ma R, Levy M, Gui B et al (2018) Risk of leptomeningeal carcinomatosis in patients with brain metastases treated with stereotactic radiosurgery. J Neurooncol 136(2):395\u2013401","journal-title":"J Neurooncol"},{"issue":"3","key":"5455_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11060-022-04190-6","volume":"160","author":"S Rajkumar","year":"2022","unstructured":"Rajkumar S, Liang Y, Wegner RE, Shepard MJ (2022) Utilization of neoadjuvant stereotactic radiosurgery for the treatment of brain metastases requiring surgical resection: a topic review. J Neurooncol 160(3):691\u2013705","journal-title":"J Neurooncol"},{"issue":"4","key":"5455_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V, Bauman G, Bradfield L et al (2022) Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol 12(4):265\u2013282","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"5455_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.brachy.2024.06.007","volume":"23","author":"T Kutuk","year":"2024","unstructured":"Kutuk T, Kotecha R, Herrera R et al (2024) Surgically targeted radiation therapy versus stereotactic radiation therapy: a dosimetric comparison for brain metastasis resection cavities. Brachytherapy 23(6):751\u2013760","journal-title":"Brachytherapy"},{"key":"5455_CR13","doi-asserted-by":"crossref","unstructured":"Nakaji P, Smith K, Youssef E et al (2020) Resection and surgically targeted radiation therapy for the treatment of larger recurrent or newly diagnosed brain metastasis: results from a prospective trial. Cureus 12(11):e11570","DOI":"10.7759\/cureus.11570"},{"issue":"3","key":"5455_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11060-022-04101-9","volume":"159","author":"BS Imber","year":"2022","unstructured":"Imber BS, Young RJ, Beal K et al (2022) Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases. J Neurooncol 159(3):609\u2013618","journal-title":"J Neurooncol"},{"issue":"6","key":"5455_CR15","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3171\/2018.7.JNS18656","volume":"131","author":"DG Brachman","year":"2018","unstructured":"Brachman DG, Youssef E, Dardis CJ et al (2018) Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. J Neurosurg 131(6):1819\u20131828","journal-title":"J Neurosurg"},{"issue":"2","key":"5455_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11060-023-04523-z","volume":"166","author":"MA Garcia","year":"2024","unstructured":"Garcia MA, Turner A, Brachman DG (2024) The role of GammaTile in the treatment of brain tumors: a technical and clinical overview. J Neurooncol 166(2):203\u2013212","journal-title":"J Neurooncol"},{"issue":"1","key":"5455_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12874-017-0436-z","volume":"17","author":"X Xue","year":"2017","unstructured":"Xue X, Agalliu I, Kim MY et al (2017) New methods for estimating follow-up rates in cohort studies. BMC Med Res Methodol 17(1):155","journal-title":"BMC Med Res Methodol"},{"key":"5455_CR18","doi-asserted-by":"crossref","unstructured":"Wen PY, Lee EQ, Al VDBM (2014) O7.01: response Assessment in Neuro-Oncology (RANO) criteria for brain metastases. Neuro Oncol 16(Suppl 2):ii15","DOI":"10.1093\/neuonc\/nou174.52"},{"issue":"4","key":"5455_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ijrobp.2013.07.034","volume":"87","author":"B Atalar","year":"2013","unstructured":"Atalar B, Modlin LA, Choi CY et al (2013) Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 87(4):713\u2013718","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl","key":"5455_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3171\/2014.6.GKS14708","volume":"121","author":"E Ojerholm","year":"2014","unstructured":"Ojerholm E, Lee JY, Thawani JP et al (2014) Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. J Neurosurg 121(Suppl):75\u201383","journal-title":"J Neurosurg"},{"issue":"2","key":"5455_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/jnnp.66.2.225","volume":"66","author":"V der Ree Tc","year":"1999","unstructured":"der Ree Tc V, Dippel DW, Avezaat CJ, Sillevis Smitt PA, Vecht CJ, van den Bent Mj (1999) Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry 66(2):225\u2013227","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"5455_CR22","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jamaoncol.2020.4630","volume":"6","author":"KA Eitz","year":"2020","unstructured":"Eitz KA, Lo SS, Soliman H et al (2020) Multi-institutional analysis of prognostic factors and outcomes after hypofractionated stereotactic radiotherapy to the resection cavity in patients with brain metastases. JAMA Oncol 6(12):1901\u20131909","journal-title":"JAMA Oncol"},{"issue":"2","key":"5455_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11060-022-04073-w","volume":"159","author":"JD Palmer","year":"2022","unstructured":"Palmer JD, Perlow HK, Matsui JK et al (2022) Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis. J Neurooncol 159(2):389\u2013395","journal-title":"J Neurooncol"},{"key":"5455_CR24","doi-asserted-by":"publisher","first-page":"110641","DOI":"10.1016\/j.radonc.2024.110641","volume":"202","author":"C Udovicich","year":"2025","unstructured":"Udovicich C, Koo K, Michael Bryant J et al (2025) International collaboration of neoadjuvant stereotactic radiosurgery for brain metastases: the INTERNEO individual patient data pooled analysis. Radiother Oncol 202:110641","journal-title":"Radiother Oncol"},{"issue":"6","key":"5455_CR25","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3171\/2020.10.JNS201934","volume":"135","author":"Roth O\u2019Brien","year":"2021","unstructured":"Roth O\u2019Brien, Kaye SM, Poppas PJ et al (2021) Time to administration of stereotactic radiosurgery to the cavity after surgery for brain metastases: a real-world analysis. J Neurosurg 135(6):1695\u20131705","journal-title":"J Neurosurg"},{"key":"5455_CR26","doi-asserted-by":"crossref","unstructured":"Dharnipragada R, Ferreira C, Shah R, Reynolds M, Dusenbery K, Chen CC (2023) GammaTile\u00ae (GT) as a brachytherapy platform for rapidly growing brain metastasis. Neurooncol Adv 5(1):vdad062","DOI":"10.1093\/noajnl\/vdad062"},{"issue":"2","key":"5455_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11060-019-03309-6","volume":"145","author":"CP Cifarelli","year":"2019","unstructured":"Cifarelli CP, Brehmer S, Vargo JA et al (2019) Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol 145(2):391\u2013397","journal-title":"J Neurooncol"},{"issue":"2","key":"5455_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1227\/NEU.0000000000001096","volume":"79","author":"KR Patel","year":"2016","unstructured":"Patel KR, Burri SH, Asher AL et al (2016 Aug) Comparing Preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: a multi-institutional analysis. Neurosurgery 79(2):279\u2013285. https:\/\/doi.org\/10.1227\/NEU.0000000000001096","journal-title":"Neurosurgery"},{"issue":"38","key":"5455_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ctro.2022.11.004","volume":"9","author":"HK Perlow","year":"2022","unstructured":"Perlow HK, Ho C, Matsui JK et al (2022 Nov) Comparing pre-operative versus post-operative single and multi-fraction stereotactic radiotherapy for patients with resectable brain metastases. Clin Transl Radiat Oncol 9(38):117\u2013122. https:\/\/doi.org\/10.1016\/j.ctro.2022.11.004","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"5455_CR30","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3171\/2024.2.JNS232426","volume":"141","author":"AN Mallela","year":"2024","unstructured":"Mallela AN, Iheagwara UK, Fogg D et al (2024 May 10) Preoperative stereotactic radiosurgery for cerebral metastases: safe, effective, and decreases steroid dependency. J Neurosurg 141(5):1332\u20131342. https:\/\/doi.org\/10.3171\/2024.2.JNS232426","journal-title":"J Neurosurg"},{"issue":"8","key":"5455_CR31","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamaoncol.2025.1770","volume":"11","author":"DN Yeboa","year":"2025","unstructured":"Yeboa DN, Li J, Lin R et al (2025 Aug 1) Therapy, Safety, and logistics of Preoperative vs postoperative stereotactic radiation therapy: a preliminary analysis of a randomized clinical trial. JAMA Oncol 11(8):890\u2013899. https:\/\/doi.org\/10.1001\/jamaoncol.2025.1770","journal-title":"JAMA Oncol"},{"issue":"1","key":"5455_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11060-025-05345-x","volume":"176","author":"J Yoo","year":"2025","unstructured":"Yoo J, Jung IH, Chang WS et al (2025 Nov 28) Neoadjuvant gamma knife surgery for metastatic brain tumor: clinical use and impact on leptomeningeal seeding. J Neurooncol 176(1):100. https:\/\/doi.org\/10.1007\/s11060-025-05345-x","journal-title":"J Neurooncol"},{"issue":"1","key":"5455_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-024-12060-","volume":"24","author":"DM Routman","year":"2024","unstructured":"Routman DM, Jusue-Torres I, Brown PD et al (2024 Mar 12) Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial. BMC Cancer 24(1):332. https:\/\/doi.org\/10.1186\/s12885-024-12060-","journal-title":"BMC Cancer"},{"issue":"3","key":"5455_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.radonc.2018.01.005","volume":"126","author":"DN Cagney","year":"2018","unstructured":"Cagney DN, Martin AM, Catalano PJ et al (2018 Mar) Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. RadiotherOncol 126(3):511\u2013518. https:\/\/doi.org\/10.1016\/j.radonc.2018.01.005","journal-title":"RadiotherOncol"},{"issue":"2","key":"5455_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijrobp.2016.01.054","volume":"95","author":"CJ Shen","year":"2016","unstructured":"Shen CJ, Kummerlowe MN, Redmond KJ, Rigamonti D, Lim MK, Kleinberg LR (2016 Jun 1) Stereotactic radiosurgery: treatment of brain metastasis without interruption of systemic therapy. Int J Radiat Oncol Biol Phys 95(2):735\u2013742. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.01.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"5455_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/neuonc\/noz006","volume":"21","author":"JM Kim","year":"2019","unstructured":"Kim JM, Miller JA, Kotecha R et al (2019 May 6) Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro Oncol 21(5):659\u2013668. https:\/\/doi.org\/10.1093\/neuonc\/noz006","journal-title":"Neuro Oncol"},{"issue":"10","key":"5455_CR37","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","volume":"35","author":"WJ Magnuson","year":"2017","unstructured":"Magnuson WJ, Lester-Coll NH, Wu AJ et al (2017 Apr 1) Management of brain metastases in tyrosine kinase inhibitor-na\u00efve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol 35(10):1070\u20131077. https:\/\/doi.org\/10.1200\/JCO.2016.69.7144","journal-title":"J Clin Oncol"},{"issue":"1","key":"5455_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3171\/2017.1.JNS162797","volume":"129","author":"R Kotecha","year":"2018","unstructured":"Kotecha R, Miller JA, Venur VA et al (2018 Jul) Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and\/or immune-based therapies on treatment outcome. J Neurosurg 129(1):50\u201359. https:\/\/doi.org\/10.3171\/2017.1.JNS162797","journal-title":"J Neurosurg"},{"issue":"8","key":"5455_CR39","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/neuonc\/noz046.9","volume":"21","author":"R Kotecha","year":"2019","unstructured":"Kotecha R, Kim JM, Miller JA et al (2019 Aug 5) The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro Oncol 21(8):1060\u20131068. https:\/\/doi.org\/10.1093\/neuonc\/noz046.9","journal-title":"Neuro Oncol"},{"issue":"2","key":"5455_CR40","doi-asserted-by":"publisher","first-page":"101349","DOI":"10.1016\/j.adro.2023.101349","volume":"9","author":"KA Katlowitz","year":"2023","unstructured":"Katlowitz KA, Beckham TH, Kudchadker RJ, Wefel J, Elamin YY, Weinberg JS (2023 Aug 15) A novel multimodal approach to refractory brain metastases: a case report. Adv Radiat Oncol 9(2):101349. https:\/\/doi.org\/10.1016\/j.adro.2023.101349","journal-title":"Adv Radiat Oncol"},{"key":"5455_CR41","doi-asserted-by":"publisher","unstructured":"Kutuk T et al (2024) Surgically targeted radiation therapy versus stereotactic radiation therapy: a dosimetric comparison for brain metastasis resection cavities. Brachytherapy. https:\/\/doi.org\/10.1016\/j.brachy.2024.06.007","DOI":"10.1016\/j.brachy.2024.06.007"},{"key":"5455_CR42","doi-asserted-by":"publisher","unstructured":"Beckham TH et al (2025) Cesium-131 collagen tile brachytherapy for salvage of recurrent intracranial metastases. J. Neuro-Oncol 1\u201310. https:\/\/doi.org\/10.1007\/s11060-025-05113-x","DOI":"10.1007\/s11060-025-05113-x"},{"key":"5455_CR43","doi-asserted-by":"publisher","unstructured":"Kutuk T et al (2023) Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: initial clinicalexperience. Brachytherapy. https:\/\/doi.org\/10.1016\/j.brachy.2023.08.002","DOI":"10.1016\/j.brachy.2023.08.002"},{"issue":"1","key":"5455_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common Terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90\u201392","journal-title":"Actas Dermosifiliogr (Engl Ed)"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05455-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05455-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05455-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:43:45Z","timestamp":1781631825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05455-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["5455"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05455-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data for this manuscript were collected from the NCT04427384 Registry Study. Although non-interventional in design, the study was reviewed and approved by the WCG-Connexus Institutional Review Board (IRB approval #20201634). Informed consent for patients in the NCT04427384 Registry Study was obtained by investigators in compliance with applicable regulations and following best clinical practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"M.J.S, C.J.S., S.H., L.S., S.L., C.C.C., and M.S.P. are consultants for GT Medical Technologies, Inc. I.L. is a consultant for Medtronic Inc. and Monteris. C.C.C. is a consultant for Medtronic Inc. and Everfront. L.S. receives research and travel support from GT Medical Technologies, Inc. E.C.P. is the owner of Biostatistical Consulting Inc., which has a consulting agreement with GT Medical Technologies, Inc. R.W. receiving funding from an Elekta research grant. R.K. reports clinical trial support from Medtronic Inc., Blue Earth Diagnostics, Ltd, Novocure Inc., GT Medical Technologies, Inc., AstraZeneca, Exelixis, Viewray Inc., Brainlab, Cantex Pharmaceuticals Inc., Ion Beam Applications, and Kazia Therapeutics Inc.; consulting fees from Kazia Therapeutics Inc., Elekta AB, Viewray Inc., Castle Biosciences, NovoCure Inc., Telix Pharmaceuticals, and GT Medical Technologies, Inc.; speaker\u2019s fees from Elekta AB, Accuray Inc., NovoCure Inc., Viewray Inc., Elsevier Inc., BrainLab, Peerview Institute for Medical Education, and Ion Beam Applications; travel support from Elekta AB, NovoCure Inc., Peerview Institute for Medical Education, Viewray Inc., BrainLab, Zap Surgical Systems, Inc., and GT Medical Technologies, Inc. He has participated in advisory boards for Viewray Inc., GT Medical Technologies, Inc., Insightec Ltd, and Plus Therapeutics, Inc. M.A.G., D.B., and S.P. are employees and stockholders of GT Medical Technologies, Inc. S.L. holds shares in Remedy Pharmaceuticals, Martin Pharmaceuticals, Woolsley Pharmaceuticals, Cytonics Corporation, and 20\/20 Gene Systems. The remaining authors declare that they have no conflicts of interest related to the preparation and submission of this manuscript, nor any other relevant disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}